223 related articles for article (PubMed ID: 8226751)
1. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
Kijima M; Yoshida M; Sugita K; Horinouchi S; Beppu T
J Biol Chem; 1993 Oct; 268(30):22429-35. PubMed ID: 8226751
[TBL] [Abstract][Full Text] [Related]
2. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells.
Yoshida H; Sugita K
Jpn J Cancer Res; 1992 Apr; 83(4):324-8. PubMed ID: 1506265
[TBL] [Abstract][Full Text] [Related]
3. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
4. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.
Kwon HJ; Owa T; Hassig CA; Shimada J; Schreiber SL
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3356-61. PubMed ID: 9520369
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function.
Yoshida M; Horinouchi S; Beppu T
Bioessays; 1995 May; 17(5):423-30. PubMed ID: 7786288
[TBL] [Abstract][Full Text] [Related]
6. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Zhou Q; Melkoumian ZK; Lucktong A; Moniwa M; Davie JR; Strobl JS
J Biol Chem; 2000 Nov; 275(45):35256-63. PubMed ID: 10938272
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
8. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
9. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
Han JW; Ahn SH; Park SH; Wang SY; Bae GU; Seo DW; Kwon HK; Hong S; Lee HY; Lee YW; Lee HW
Cancer Res; 2000 Nov; 60(21):6068-74. PubMed ID: 11085529
[TBL] [Abstract][Full Text] [Related]
10. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
Yoshida M; Kijima M; Akita M; Beppu T
J Biol Chem; 1990 Oct; 265(28):17174-9. PubMed ID: 2211619
[TBL] [Abstract][Full Text] [Related]
11. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
12. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.
Taunton J; Hassig CA; Schreiber SL
Science; 1996 Apr; 272(5260):408-11. PubMed ID: 8602529
[TBL] [Abstract][Full Text] [Related]
13. Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8.
Porter NJ; Christianson DW
ACS Chem Biol; 2017 Sep; 12(9):2281-2286. PubMed ID: 28846375
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin.
Sternson SM; Wong JC; Grozinger CM; Schreiber SL
Org Lett; 2001 Dec; 3(26):4239-42. PubMed ID: 11784187
[TBL] [Abstract][Full Text] [Related]
15. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.
Itazaki H; Nagashima K; Sugita K; Yoshida H; Kawamura Y; Yasuda Y; Matsumoto K; Ishii K; Uotani N; Nakai H
J Antibiot (Tokyo); 1990 Dec; 43(12):1524-32. PubMed ID: 2276972
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
Kim YB; Ki SW; Yoshida M; Horinouchi S
J Antibiot (Tokyo); 2000 Oct; 53(10):1191-200. PubMed ID: 11132966
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
18. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
[TBL] [Abstract][Full Text] [Related]
19. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Saito A; Yamashita T; Mariko Y; Nosaka Y; Tsuchiya K; Ando T; Suzuki T; Tsuruo T; Nakanishi O
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4592-7. PubMed ID: 10200307
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
